{
    "title": "114_hr639",
    "content": "The Act titled \"Improving Regulatory Transparency for New Medical Therapies Act\" amends the Federal Food, Drug, and Cosmetic Act to delay drug approval until controls under the Controlled Substances Act are issued. The Act \"Improving Regulatory Transparency for New Medical Therapies Act\" delays drug approval until controls under the Controlled Substances Act are issued, with the date of approval defined as the later of the approval date or the issuance of the interim final rule controlling the drug. The Act delays drug approval until controls under the Controlled Substances Act are issued, with the date of approval defined as the later of the approval date or the issuance of the interim final rule controlling the drug. The biological product approval process is tied to the issuance of controls under the Controlled Substances Act. The date of approval is determined as the later of the approval date or the issuance of the interim final rule controlling the product. The Cosmetic Act is amended to delay approval for drugs recommended for controls under the Controlled Substances Act until the interim final rule is issued. The \"date of approval\" is defined as the later of the approval date or the issuance of the interim final rule. The Federal Food, Drug, and Cosmetic Act is amended to delay approval for drugs recommended for controls under the Controlled Substances Act until the issuance of the interim final rule. The Secretary intends to issue a scientific and medical evaluation for a sponsor's application under the Controlled Substances Act. Conditional approval will not take effect until the interim final rule controlling the drug is issued. The term 'date of approval' for such applications is defined as the later of the conditional approval date or the issuance date of the interim final rule. Additionally, the indexing of legally marketed unapproved new animal drugs is addressed in Section 572 of the Federal Food, Drug, and Cosmetic Act. The amendment to Section 572 of the Federal Food, Drug, and Cosmetic Act addresses the indexing of legally marketed unapproved new animal drugs. A request to add a drug to the index will not take effect until an interim final rule controlling the drug is issued under the Controlled Substances Act. The amendment to Section 573(c) of the Federal Food, Drug, and Cosmetic Act states that for newly approved animal drugs, the 7-year exclusivity period will not start until the interim final rule controlling the drug is issued under the Controlled Substances Act. The Controlled Substances Act is amended to include a provision for newly approved drugs, requiring the Attorney General to issue an interim final rule within 90 days of receiving a recommendation from the Secretary of Health and Human Services. The Attorney General must issue an interim final rule within 90 days of receiving a recommendation from the Secretary of Health and Human Services for newly approved drugs. The rule becomes immediately effective without needing a demonstration of good cause. The Attorney General must issue an interim final rule within 90 days of receiving a recommendation for newly approved drugs. The rule becomes immediately effective without needing a demonstration of good cause. Additionally, Section 156 of title 35, United States Code, is amended to extend the patent term for drug products. In subsection (d)(1), a provision is added for drug products described in subsection (i) to be marketed within sixty days of the covered date. Section (i) states that if the Secretary of Health and Human Services notifies the sponsor of a drug product for Controlled Substances Act controls, the product is considered approved for commercial use. The product is considered approved for commercial use under specific provisions of the Public Health Service Act or Federal Food, Drug, and Cosmetic Act. The term 'covered date' refers to the later of various approval dates or the issuance of an interim final rule controlling the drug under the Controlled Substances Act. SEC. 3. ENHANCING NEW DRUG DEVELOPMENT. Amends Section 303 of the Controlled Substances Act to expedite registration for manufacturing controlled substances for clinical trials. The Attorney General must register the applicant within 180 days of application acceptance. SEC. 4. RE-EXPORTATION AMONG MEMBERS OF THE EUROPEAN ECONOMIC AREA. The Attorney General must issue a notice of application within 90 days for controlled substances used in clinical trials, and register the applicant within 90 days after the comment period ends. The Attorney General must serve an order to show cause on the applicant under section 304(c) of the Controlled Substances Import and Export Act. Section 1003 is amended to allow re-exportation among members of the European Economic Area. Subsequent to re-exportation among members of the European Economic Area, controlled substances can continue to be exported between these countries if certain conditions are met. Substances can be exported between countries in the European Economic Area if conditions are met, including providing documentation and information on re-exportation within 30 days. The Attorney General must receive documentation certifying re-exportation and information on the consignee, country, and product. The Attorney General is restricted from impeding re-exportation of controlled substances among European Economic Area countries, including not enforcing time restrictions or information requirements on re-exportation. Re-exportation of controlled substances between countries must occur within a specified time period, or information on consignee, country, and product must be provided before exportation. The curr_chunk is about the roles of the Speaker of the House of Representatives and the Vice President of the United States as President of the Senate."
}